MHRA rare disease plan could speed UK treatment access

When we hear 'rare disease', it is easy to picture a tiny issue. The MHRA's own figures tell a different story: more than 3.5 million people in the UK live with a rare disease, around one in 17 people, and on 21 May 2026 the regulator opened a public consultation on a new framework meant to help some treatments move from lab to clinic more quickly and at lower cost. (gov.uk) If you have never had to think about medicine regulation before, start here. The present system was mostly built around common illnesses, where researchers can recruit lots of people and gather neat sets of trial data. The MHRA is now asking whether that model still works when a condition may affect only a few families. (gov.uk)

Rare disease is not one single medical category. In the MHRA press release, the examples range from inherited retinal dystrophies and Angelman syndrome to DHDDS-related neurological disease, ultra-rare cancers and myotonic dystrophy. What links them is not that they look alike, but that patients often hit the same wall: long waits, tiny patient groups and very few approved treatments. (gov.uk) The gap is stark. According to the MHRA, fewer than 5% of rare diseases currently have an approved treatment, the average diagnostic wait is more than five years, and 30% of children affected by rare diseases die before the age of five. (gov.uk)

The draft framework is aimed at very rare conditions affecting no more than one in 50,000 people, where there are measurable barriers to running a standard clinical trial. Entry would depend on factors such as how severe the disease is and whether there is an unmet need. (gov.uk) This is the bit that matters for general readers. In a common illness, researchers might compare hundreds or thousands of patients across groups. In a condition affecting only a handful of people, that model can fall apart before recruitment even starts. The GOV.UK consultation page says these cases may need adaptive trials, prior knowledge, predictive modelling and real-world data to build an evidence picture. (gov.uk)

The biggest proposed change is something called an Investigational Marketing Authorisation, or IMA. In plain English, that would combine clinical trial approval with a step-by-step path towards a full marketing authorisation, instead of forcing developers through two separate systems from the start. The MHRA says this could allow controlled early access to a therapy while more clinical and real-world evidence is gathered. (gov.uk) **What this means:** patients might be able to get promising treatments earlier, but this would not be a blank cheque. The press release says any NHS use would still depend on NICE, which decides whether a treatment should be used in the health service and whether it offers value for money. (gov.uk)

This is also why the proposal is not simply 'faster approval'. The draft puts real weight on monitoring after access begins, on clear communication with patients, and on informed consent as something that should be revisited over time rather than treated as a form signed once and forgotten. (gov.uk) For readers who hear 'flexible' and worry that it means weaker checks, the MHRA's case is the opposite. The idea is to change the kind of evidence accepted when patient numbers are tiny, while keeping safety, quality and efficacy standards in place. That balancing act sits underneath the whole consultation. (gov.uk)

There is a money question here too, and it is not just about company costs. The MHRA says delayed diagnosis alone is estimated to cost £340 million a year, with another £4.7 billion in health-related disability costs and a £14.9 billion annual hit to the wider UK economy. It also says the present route can make development so difficult and expensive that companies do not see a workable case for investment. (gov.uk) **Why it matters:** when the system assumes large trials for tiny patient groups, patients pay in time and uncertainty, while developers pay in cost and risk. The MHRA argues that compressing the pathway could reduce development costs and may make some medicines more affordable. (gov.uk)

This did not appear overnight. The MHRA first signalled a rare disease rule change in November 2025, and the current draft has been shaped with a Rare Disease Consortium that includes patient organisations, universities, hospitals, NHS bodies, NICE and industry partners. That matters because it means the proposal has been built with both regulators and people living close to the issue. (gov.uk) It is also still only a draft. NICE has said the framework could sit alongside its own approach of allowing promising medicines to reach NHS patients while extra evidence is collected, and groups such as Genetic Alliance UK have welcomed the proposal while stressing that the detail now matters. That feels like the right tone for all of us to keep in mind: hopeful, but not unquestioning. (gov.uk)

If you want to have your say, the consultation is open to patients, families, carers, clinicians, researchers and members of the public. The live GOV.UK consultation page says responses close at 11.59pm on 30 July 2026. (gov.uk) The bigger lesson reaches beyond rare disease care. Systems built for the average case can fail people at the edges, even when everyone involved says the right things. The MHRA is now testing whether the rules can catch up with the science. For families who have already waited years, that question is not abstract at all. (gov.uk)